Feasibility of MRI-guided focal salvage high-dose-rate brachytherapy for locally recurrent prostate cancer

niversity Medical Center Utrecht0 个研究点目标入组 30 人开始时间: 待定最近更新: 2024年2月28日

适应症

试验速览

one

•Age >18 years;
•-Biopsy proven local recurrence;
•-Biopsy proven recurrence at least 2 years after primary radiotherapy treatment (low-dose-rate brachytherapy or external beam radiation therapy);
•-Limited and non-aggressive tumor presentation at time of salvage (PSA at time of salvage <10);
•-PSA doubling time more than 12 months;
•-Acceptable toxicity of primary radiation treatment (IPSS<15);
•-Tumour location technically feasible for brachytherapy;
•-Tumour on MRI and PSMA/choline PET scan within anatomical prostate borders (no extracapsular growth or metastases);
•-Karnofsky score >70;
•-Written informed consent;
•-Fit for anaesthesia.

•-Distant metastases;
•-Severe toxicity from primary radiation treatment (IPSS>15);
•-Patients who meet exclusion criteria for MRI following the protocol of the radiology department of the UMC Utrecht (see appendix);
•-Anticoagulant administration continuously required, except for Ascal;
•-Discongruence between prostate biopsies and contrast MR imaging;
•-Prior prostate treatment(s) (like a recent TURP (<6 months before focal salvage HDR treatment), HIFU, cryosurgery), except for radiotherapy.

发起方